mRNA Vaccine Delivery Using Lipid Nanoparticles
Open Access
- 14 April 2016
- journal article
- review article
- Published by Informa UK Limited in Therapeutic Delivery
- Vol. 7 (5), 319-334
- https://doi.org/10.4155/tde-2016-0006
Abstract
MRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells. mRNA vaccines are currently evaluated in clinical trials for cancer immunotherapy applications, but also have great potential as prophylactic vaccines. Efficient delivery of mRNA vaccines will be key for their success and translation to the clinic. Among potential nonviral vectors, lipid nanoparticles are particularly promising. Indeed, lipid nanoparticles can be synthesized with relative ease in a scalable manner, protect the mRNA against degradation, facilitate endosomal escape, can be targeted to the desired cell type by surface decoration with ligands, and as needed, can be codelivered with adjuvants.Keywords
This publication has 146 references indexed in Scilit:
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**Angewandte Chemie-International Edition, 2012
- Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNAMolecular Therapy Nucleic Acids, 2012
- Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting CellsMolecular Therapy, 2011
- Negatively Charged Liposomes Show Potent Adjuvant Activity When Simply Admixed with Protein AntigensMolecular Pharmaceutics, 2011
- Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and ImmunityImmunity, 2011
- TLR-based immune adjuvantsVaccine, 2010
- Stealth nanoparticles: High density but sheddable PEG is a key for tumor targetingJournal of Controlled Release, 2010
- Viral vectors: from virology to transgene expressionBritish Journal of Pharmacology, 2009
- A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA DeliveryMolecular Pharmaceutics, 2009
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008